HK1223547A1 - 癌症治療方法 - Google Patents

癌症治療方法

Info

Publication number
HK1223547A1
HK1223547A1 HK16111783.0A HK16111783A HK1223547A1 HK 1223547 A1 HK1223547 A1 HK 1223547A1 HK 16111783 A HK16111783 A HK 16111783A HK 1223547 A1 HK1223547 A1 HK 1223547A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
methods
Prior art date
Application number
HK16111783.0A
Other languages
English (en)
Inventor
.古德諾
.奧登特里科
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of HK1223547A1 publication Critical patent/HK1223547A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
HK16111783.0A 2013-05-03 2016-10-12 癌症治療方法 HK1223547A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
PCT/US2014/036651 WO2014179738A1 (en) 2013-05-03 2014-05-02 Methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1223547A1 true HK1223547A1 (zh) 2017-08-04

Family

ID=51843995

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111783.0A HK1223547A1 (zh) 2013-05-03 2016-10-12 癌症治療方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (zh)
JP (2) JP2016522188A (zh)
KR (1) KR102337598B1 (zh)
CN (1) CN105492007A (zh)
HK (1) HK1223547A1 (zh)
WO (1) WO2014179738A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180353602A1 (en) * 2015-06-29 2018-12-13 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
KR20240042244A (ko) * 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. 조합 요법
KR20210029190A (ko) * 2018-06-06 2021-03-15 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1861094A4 (en) * 2005-03-11 2014-06-11 Univ Colorado HISTONDEACETYLASE INHIBITORS SENSITIZE CANCER CELLS FOR EPIDERMAL GROWTH FACTOR INHIBITORS
CA2658170A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20100305167A1 (en) * 2007-11-19 2010-12-02 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC
BRPI0909818A2 (pt) * 2008-03-07 2015-10-06 Pfizer métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
WO2009126662A1 (en) * 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
EA201201474A1 (ru) * 2011-09-02 2013-08-30 Синдэкс Фармасьютикалс, Инк. Способы лечения рака молочной железы

Also Published As

Publication number Publication date
JP2019112416A (ja) 2019-07-11
JP6860949B2 (ja) 2021-04-21
KR20160003182A (ko) 2016-01-08
KR102337598B1 (ko) 2021-12-10
WO2014179738A1 (en) 2014-11-06
EP2991650A4 (en) 2017-01-25
CN105492007A (zh) 2016-04-13
JP2016522188A (ja) 2016-07-28
EP2991650A1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
HK1220155A1 (zh) 治療癌症的方法
SG11201508223YA (en) Treatment of cancer with dihydropyrazino-pyrazines
ZA201507733B (en) Treatment of cancer with dihydropyrazino-pyrazines
HK1213817A1 (zh) 治療癌症的方法
HK1222548A1 (zh) 治療惡性腫瘤的藥物組合
EP3008212A4 (en) Methods of treatment of cancer
HK1219737A1 (zh) 用於治療癌症的新化合物
HK1219513A1 (zh) 治療癌症的方法
HK1223547A1 (zh) 癌症治療方法
IL245551A0 (en) Anti-matriptase antibodies for cancer treatment
LT3016682T (lt) Vėžio gydymo būdai
GB201607581D0 (en) Treatment of cancer
HK1221681A1 (zh) 用於治療神經退化的方法
HK1232118A1 (zh) 癌症的治療
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
AP2015008905A0 (en) Novel compounds for the treatment of cancer
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201322346D0 (en) Combination treatment of cancer
GB201308529D0 (en) Treatment of cancer
GB201305020D0 (en) Treatment of cancer
GB201300546D0 (en) Cancer Treatment